Breaking Down Data Silos to Improve Clinical Workflow Efficiency and Reduce Physician Burnout with Craig Limoli Wellsheet TRANSCRIPT
Release Date: 08/07/2025
Developing Immunotherapy to Fight Bone Cancer with Paul Romness and Olivia Egge OS Therapies TRANSCRIPT
Empowered Patient Podcast
Paul Romness, Chairman, CEO, and President of OS Therapies, and Olivia Egge, a member of the Board of Directors of OS Therapies, discuss osteosarcoma, a rare and aggressive form of bone cancer that primarily affects teenagers. OS Therapies is developing an immunotherapy that utilizes a weakened form of the listeria bacteria to stimulate the immune system and prevent the spread of cancer cells to the lungs and brain. Olivia's experience as a patient has motivated her to advocate for better treatment options and join the board of OS Therapeutics. Paul explains, "So osteosarcoma is quite...
info_outline
Developing Immunotherapy to Fight Bone Cancer with Paul Romness and Olivia Egge OS Therapies
Empowered Patient Podcast
Paul Romness, Chairman, CEO, and President of OS Therapies, and Olivia Egge, a member of the Board of Directors of OS Therapies, discuss osteosarcoma, a rare and aggressive form of bone cancer that primarily affects teenagers. OS Therapies is developing an immunotherapy that utilizes a weakened form of the listeria bacteria to stimulate the immune system and prevent the spread of cancer cells to the lungs and brain. Olivia's experience as a patient has motivated her to advocate for better treatment options and join the board of OS Therapeutics. Paul explains, "So osteosarcoma is quite...
info_outline
New Inhibitor Drug Transforms Cancer Treatment Accessibility with Dan Schmitt Actuate Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option. Dan explains, "So, GSK-3β is a known...
info_outline
New Inhibitor Drug Transforms Cancer Treatment Accessibility with Dan Schmitt Actuate Therapeutics
Empowered Patient Podcast
Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option. Dan explains, "So, GSK-3β is a known...
info_outline
Democratizing Molecular Diagnostics Transforming Transplant Success with Andrea James iMDx TRANSCRIPT
Empowered Patient Podcast
Andrea James, Chief Financial Officer at iMDx, is focused on expanding access to innovative molecular diagnostic testing staring with a test for monitoring transplanted organ health. The test measures the donor-derived cell-free DNA which can indicate the need for drugs to target organ rejection before invasive procedures are required. The company is developing a kit-based version of the test that can be run by hospitals rather than relying on centralized labs, to increase access to this diagnostic and improve transplant outcomes. Andrea explains, "We changed our name on June 17th from...
info_outline
Democratizing Molecular Diagnostics Transforming Transplant Success with Andrea James iMDx
Empowered Patient Podcast
Andrea James, Chief Financial Officer at iMDx, is focused on expanding access to innovative molecular diagnostic testing staring with a test for monitoring transplanted organ health. The test measures the donor-derived cell-free DNA which can indicate the need for drugs to target organ rejection before invasive procedures are required. The company is developing a kit-based version of the test that can be run by hospitals rather than relying on centralized labs, to increase access to this diagnostic and improve transplant outcomes. Andrea explains, "We changed our name on June 17th from...
info_outline
Healthcare Financial Recovery Driven by Focus on People First with James Hereford Fairview Health Services TRANSCRIPT
Empowered Patient Podcast
James Hereford, President and CEO of Fairview Health Services, describes this Minnesota-based healthcare system's $600 million turnaround and the importance of focusing on people and processes, not just technology changes. Addressing staff shortages, quality of care, and patient experience led to finding a holistic approach that improved financial outcomes and changed the culture in a sustainable way. Investments have been made in community programs like food access and vaccination events, recognizing the impact of social determinants of health on patient outcomes. James explains, "When doing...
info_outline
Healthcare Financial Recovery Driven by Focus on People First with James Hereford Fairview Health Services
Empowered Patient Podcast
James Hereford, President and CEO of Fairview Health Services, describes this Minnesota-based healthcare system's $600 million turnaround and the importance of focusing on people and processes, not just technology changes. Addressing staff shortages, quality of care, and patient experience led to finding a holistic approach that improved financial outcomes and changed the culture in a sustainable way. Investments have been made in community programs like food access and vaccination events, recognizing the impact of social determinants of health on patient outcomes. James explains, "When doing...
info_outline
Innovative Homeostasis Focused Drugs to Treat Root Causes of Disease with Steve Butts Arrivo BioVentures TRANSCRIPT
Empowered Patient Podcast
teve Butts, Co-Founder and CEO of Arrivo BioVentures, is a biopharmaceutical company focused on developing therapies that target the root causes of disease rather than just treating the symptoms. Their drugs treat major depressive disorder and acute pancreatitis through novel epigenetic mechanisms of action. Sex-based differences were observed in clinical trials where the drug SP-624 showed efficacy in females but not in males, which could lead to a paradigm shift in how depression is treated in men and women. Steve explains, "We've evolved over time at Arrivo and with our previous companies....
info_outline
Innovative Homeostasis Focused Drugs to Treat Root Causes of Disease with Steve Butts Arrivo BioVentures
Empowered Patient Podcast
Steve Butts, Co-Founder and CEO of Arrivo BioVentures, is a biopharmaceutical company focused on developing therapies that target the root causes of disease rather than just treating the symptoms. Their drugs treat major depressive disorder and acute pancreatitis through novel epigenetic mechanisms of action. Sex-based differences were observed in clinical trials where the drug SP-624 showed efficacy in females but not in males, which could lead to a paradigm shift in how depression is treated in men and women. Steve explains, "We've evolved over time at Arrivo and with our previous...
info_outlineCraig Limoli, Co-Founder and CEO of Wellsheet, is streamling workflows for clinicians by providing better access to patient data and improving care coordination across care teams. Wellsheet is integrated into existing health records to provide a seamless experience to users and help to reduce "pajama time" for doctors by reducing the amount of end-of-the-day work needed to document patient encounters. Wellsheet uses AI and natural language processing to surface the most relevant information for clinicians and generate documentation, reducing time spent and improving efficiency.
Craig explains, "Wellsheet is a care team, co-pilot that serves physicians as well as other clinicians with better access to all of the data they need to make treatment decisions for patients, as well as easier coordination across the whole care team. So we're really designed as a company and as a product to support a broad array of clinicians, both physicians, nursing case managers, and surface the data most relevant to them in the way that they want to see it. We coordinate care across those multidisciplinary stakeholders in a way that is seamlessly embedded and integrated into the existing electronic health record systems to ultimately create a really seamless and cohesive experience for our users."
"So our technology is embedded within Epic, Cerner, and other major EHRs. So physicians and other clinicians access it with the click of a button directly within their workflow in the EHR. They don't have to log in again, they don't have to reidentify the patient. It all feels like a native part of their EHR experience. And as soon as they click into Wellsheet, they are presented with a summarized view of the most relevant information from the entire patient's medical history and what pertains to that particular encounter, all in a single place."
#Wellsheet #ClinicalWorkflow #EHR #AI #ClinicalAI #MultidisciplinaryCare #PhysicianBurnout #DigitalHealth
